Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 1;8(7):201.
doi: 10.3390/toxins8070201.

Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis

Affiliations
Review

Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis

Bin Chiu et al. Toxins (Basel). .

Abstract

Botulinum neurotoxin A (BoNT-A), derived from Clostridium botulinum, has been used clinically for several diseases or syndrome including chronic migraine, spasticity, focal dystonia and other neuropathic pain. Chronic pelvic or bladder pain is the one of the core symptoms of bladder pain syndrome/interstitial cystitis (BPS/IC). However, in the field of urology, chronic bladder or pelvic pain is often difficult to eradicate by oral medications or bladder instillation therapy. We are looking for new treatment modality to improve bladder pain or associated urinary symptoms such as frequency and urgency for patients with BPS/IC. Recent studies investigating the mechanism of the antinociceptive effects of BoNT A suggest that it can inhibit the release of peripheral neurotransmitters and inflammatory mediators from sensory nerves. In this review, we will examine the evidence supporting the use of BoNTs in bladder pain from basic science models and review the clinical studies on therapeutic applications of BoNT for BPS/IC.

Keywords: botulinum toxin A; cystitis; interstitial cystitis; intravesical injection.

PubMed Disclaimer

References

    1. Van de Merwe J.P., Nordling J., Bouchelouche P., Bouchelouche K., Cervigni M., Daha L.K., Elneil S., Fall M., Hohlbrugger G., Irwin P., et al. Diagnostic criteria, classification, and nomenclature for painfulbladder syndrome/interstitial cystitis: An ESSIC proposal. Eur. Urol. 2008;53:60–67. doi: 10.1016/j.eururo.2007.09.019. - DOI - PubMed
    1. Hanno P.M., Burks D.A., Clemens J.Q., Dmochowski R.R., Erickson D., Fitzgerald M.P., Forrest J.B., Gordon B., Gray M., Mayer R.D., et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 2011;185:2162–2170. doi: 10.1016/j.juro.2011.03.064. - DOI - PMC - PubMed
    1. Curhan G.C., Speizer F.E., Hunter D.J., Curhan S.G., Stampfer M.J. Epidemiology of interstitial cystitis: A population based study. J. Urol. 1999;161:549–552. doi: 10.1016/S0022-5347(01)61947-5. - DOI - PubMed
    1. Mayer R. Interstitial cystitis pathogenesis and treatment. Curr. Opin. Infect. Dis. 2007;20:77–82. doi: 10.1097/QCO.0b013e32801158df. - DOI - PubMed
    1. Nazif O., Teichman J.M., Gebhart G.F. Neural upregulation in interstitial cystitis. Urology. 2007;69:24–33. doi: 10.1016/j.urology.2006.08.1108. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources